Three Research Peptides, One Axis

The short version

Gurl Peptide is a reading desk, not a store. It collects what the published research literature actually says about three peptides that keep coming up in conversations about sexual desire, arousal and the reproductive hormone axis: PT-141, Kisspeptin and Melanotan II. A peptide is a short chain of amino acids — the same building blocks that make up proteins, only far smaller. Each of these three has been studied because it interacts with a part of the nervous or endocrine system that governs sexual motivation, arousal or reproductive hormone signaling.

PT-141 (bremelanotide) is the most clinically advanced: a cyclic heptapeptide that activates melanocortin receptors in the brain and has an FDA-approved drug form for a specific indication in premenopausal women. Kisspeptin is a neuropeptide that sits at the top of the reproductive hormone cascade, stimulating the brain's own GnRH neurons — an entirely different mechanism from the melanocortin pathway. Melanotan II is a non-selective melanocortin agonist studied both for skin-darkening and for effects on erections; it carries real safety cautions and is not approved for any use.

This desk does one job: it tells you, in plain language and with citations, what each peptide was tested on, in which species, and how far that evidence actually reaches. It stops well short of human dosing advice. None of these is a recommended treatment. We do not sell anything, and we never list a human dose.

What are research peptides?

Proteins in your body — a hormone, an enzyme, a structural fiber — are long chains of amino acids folded into a specific shape. A peptide is a much shorter chain of the same amino acids, sometimes only a handful of links long. Because they are small and specific, peptides can act like keys that fit particular locks (receptors) on cell surfaces, switching certain processes on or off.

A research peptide is one that has been synthesized and studied in the laboratory — in cell cultures, in animals, occasionally in early human pilots — but has not been approved by a regulator as a medicine (or whose approved form is different from the research-chemical version being discussed). Sellers describe these compounds as being for laboratory research only, and that framing matters: it means dosing, long-term safety and real-world effectiveness in people are usually unestablished. When this site reports a number, it reports it the way the study did — for example, studied at 0.025 mg/kg in men with psychogenic erectile dysfunction — never as a recommendation. PT-141 is the partial exception: an FDA-approved pharmaceutical form, bremelanotide, exists for a narrow indication. Research-grade PT-141 and that pharmaceutical are not the same thing.

How these three fit into desire and arousal research

The three peptides on this desk work through overlapping but distinct mechanisms, which is why they sit together.

• PT-141 is the lead. It is a cyclic heptapeptide derived from Melanotan II and acts centrally on MC4R (and MC3R) receptors in the hypothalamus and limbic system — not on blood vessels, not on the HPG axis ^[7]. Two pivotal Phase 3 trials found it improved sexual desire and reduced desire-related distress in premenopausal women with HSDD ^[3]. Its research-chemical form sits outside the pharmaceutical approval.
• Kisspeptin works at the top of the reproductive cascade: it binds KISS1R on hypothalamic GnRH neurons and drives pulsatile LH and FSH secretion, which in turn raises downstream sex-steroid output ^[12]. A 2022 neuroimaging study found that MC4R agonism — closely related mechanism — altered brain responses to erotic stimuli in women with HSDD ^[2], and kisspeptin has also been linked to sexual motivation in its own right. No kisspeptin product is approved for any indication.
• Melanotan II is the broadest-acting of the three: a non-selective agonist across all five melanocortin receptor subtypes. Its skin-darkening effect comes from MC1R; its sexual and appetite effects come from central MC4R ^[16]. An early controlled crossover study found it produced erections in men with psychogenic ED ^[17]. It was never advanced to late-phase trials and carries documented safety concerns.

Together they map the desire-arousal space from three angles: central melanocortin signaling (PT-141), the upstream reproductive hormone axis (Kisspeptin), and broad non-selective melanocortin activity (Melanotan II). Use the directory to read each one, or compare these peptides side by side.

A note on how this desk reads the literature

Gurl Peptide is a cross-referenced literature digest. Each peptide page summarizes the peer-reviewed studies for that compound, cites them by number, and links to a single shared references list that aggregates every source across all three. Where the evidence is thin, preclinical only, or carries safety cautions, we say so plainly. We describe research findings and the cited cautions that come with them; we do not recommend, prescribe, or sell. The aim is an accurate map of what is known — so you can see where the science is solid and where it is still incomplete.